Tatum and Umezaki?

The collaboration between Edward Tatum and Dorothy Umezaki at the University of Wisconsin in 1968 marked a turning point in how serum therapy could be rationally designed and applied. Their work demonstrated that the effectiveness of passive immunization depended fundamentally on matching the serum to the precise genetic strain responsible for infection, rather than treating bacterial disease as a monolithic category. This insight transformed serum therapy from empirical trial-and-error into a discipline capable of targeted response.

Tatum arrived in Madison in 1966, already established in the field of bacterial genetics through decades of work with metabolic mutations in Neurospora and Escherichia coli. Umezaki came to Wisconsin as a postdoctoral researcher in 1967, following a distinguished career in immunology at the Pasteur Institute in Paris and the Infectious Disease Research Centre in Cambridge. Their proximity within the same department was fortuitous. Madison had become a secondary hub for bacteriology in the postwar decades, drawing researchers interested in genetic approaches to infection at a time when chemical therapy remained limited to the azo drugs.

The two began studying serum responses in a collection of clinical isolates drawn from different patients with bacteraemia. What they found was striking: serums prepared against one isolate often failed completely against another, even when both bacteria were identified as the same species under standard laboratory classification. The genetic basis of this variation had never been systematically explored. Using the new techniques of bacterial genetics, they mapped the surface antigens responsible for immune recognition across dozens of strains and began tracing the genetic loci that encoded them. Their 1969 paper in Nature, co-authored with three Wisconsin graduate students, showed that a single point mutation in a flagellar-antigen gene could render a serum therapy completely ineffective against an otherwise identical bacterium.

This work had immediate practical consequences. It explained why some hospital populations responded well to a given serum therapy while others in distant cities did not. It suggested that serum therapy could be improved through targeted harvesting—immunizing animals against the most prevalent local strains rather than using a single standard preparation. The Geneva Sanitary Bureau, which had spent the 1960s struggling to standardize serum therapy protocols despite wildly inconsistent clinical outcomes, suddenly had a framework for understanding those failures.

Umezaki's subsequent career focused on mapping the genetic variation among clinically important strains of Staphylococcus aureus, Streptococcus pyogenes, and Pseudomonas aeruginosa. In the early 1970s, she began establishing regional serum banks matched to local strain populations—an innovation that required coordination with specialized serum farms and hospital systems across multiple countries. Her work at Cambridge from 1971 onward fed directly into the development of the Halloway-Umezaki method, which incorporated strain-matched serum preparation as a core component. Tatum remained in Madison, pursuing the more theoretical genetics of virulence factors, but continued to collaborate with Umezaki on publications and served as a consultant to the International Serum Registry when it was founded in 1975.

Their relationship was professional and productive but never publicly close. Both were reserved figures; Umezaki published with methodical precision and gave few interviews, while Tatum maintained the careful distance of an established researcher supervising younger colleagues' work. What drove them was a shared conviction that the absence of chemical cure made the genetics of infection not just academically interesting but medically urgent. As Tatum remarked in a 1976 oral history, collected by the Institute for the History of Bacteriology, "if bacteria could change, we had to understand how they changed. That was the only therapeutic handle we had."

The Wisconsin collaboration of 1968–1970 lasted barely two years before Umezaki moved back to Cambridge. By then the intellectual framework was established. Their work did not solve the problem of untreatable infection, but it made infection treatment rational in a way the older serum therapy had not been—empirical but explainable, variable but mappable, and subject to systematic improvement through knowledge of bacterial genetics.